| 4/15/2022 |
Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection |
| 3/21/2022 |
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins |
| 12/22/2021 |
Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection |
| 11/3/2021 |
Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms |
| 10/5/2021 |
Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation |
| 8/31/2021 |
Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence |
